Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Erythrocytes01:27

Disorders of Erythrocytes

2.5K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
2.5K
Rh Blood Group01:19

Rh Blood Group

4.2K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
4.2K
Erythropoiesis01:14

Erythropoiesis

5.6K
Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
5.6K
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

12.6K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
12.6K
Lifecycle of Erythrocytes01:22

Lifecycle of Erythrocytes

5.5K
Erythrocytes, also known as red blood cells, constantly move through blood capillaries. As a result, they damage their plasma membrane due to the continuous friction. Typically, after 100 to 120 days, erythrocytes become rigid and fragile as they wear out. As they pass through small vessels in the spleen and liver, they can get trapped and break apart into fragments.
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups....
5.5K
Blood Transfusion01:15

Blood Transfusion

3.0K
Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: PIGN spatiotemporally regulates the spindle assembly checkpoint proteins in leukemia transformation and progression.

Scientific reports·2026
Same author

Noninvasive Monitoring of Complement Using the Bioluminescent Modified Ham Assay in the Second Porcine-to-Human Live Heart Transplant.

Xenotransplantation·2026
Same author

Defining "Dominance" in Atypical Hemolytic Uremic Syndrome: Distinguishing Amplification From Initiation.

Kidney international reports·2026
Same author

Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry.

American journal of hematology·2026
Same author

Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy.

Blood advances·2026
Same author

Bone marrow transplantation for sickle cell disease using posttransplantation cyclophosphamide and 400 cGy TBI.

Blood advances·2026
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Related Experiment Video

Updated: Apr 23, 2026

Author Spotlight: Enhancing Vascular Function and Physical Capacity in Cardiovascular Disease Through Novel Interventions and NIRS Technology
04:44

Author Spotlight: Enhancing Vascular Function and Physical Capacity in Cardiovascular Disease Through Novel Interventions and NIRS Technology

Published on: March 22, 2024

1.7K

Paroxysmal nocturnal hemoglobinuria.

Robert A Brodsky1

  • 1Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

Blood
|September 20, 2014
PubMed
Summary
This summary is machine-generated.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder causing anemia and blood issues due to complement activation. Eculizumab treats severe PNH, while bone marrow transplant offers a cure for non-responders.

More Related Videos

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples
05:17

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples

Published on: July 28, 2016

9.4K
Induction of Eryptosis in Red Blood Cells Using a Calcium Ionophore
09:15

Induction of Eryptosis in Red Blood Cells Using a Calcium Ionophore

Published on: January 21, 2020

8.3K

Related Experiment Videos

Last Updated: Apr 23, 2026

Author Spotlight: Enhancing Vascular Function and Physical Capacity in Cardiovascular Disease Through Novel Interventions and NIRS Technology
04:44

Author Spotlight: Enhancing Vascular Function and Physical Capacity in Cardiovascular Disease Through Novel Interventions and NIRS Technology

Published on: March 22, 2024

1.7K
Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples
05:17

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples

Published on: July 28, 2016

9.4K
Induction of Eryptosis in Red Blood Cells Using a Calcium Ionophore
09:15

Induction of Eryptosis in Red Blood Cells Using a Calcium Ionophore

Published on: January 21, 2020

8.3K

Area of Science:

  • Hematology
  • Immunology
  • Genetics

Background:

  • Paroxysmal nocturnal hemoglobinuria (PNH) is a rare bone marrow failure disorder characterized by hemolytic anemia, thrombosis, and cytopenias.
  • The deficiency of glycosylphosphatidylinositol (GPI)-anchored proteins CD55 and CD59 results in uncontrolled complement activation, driving PNH pathology.
  • Somatic mutations in the PIGA gene are the primary cause of GPI anchor protein deficiency in PNH.

Purpose of the Study:

  • To summarize the pathophysiology of PNH, focusing on complement activation and GPI anchor protein deficiency.
  • To discuss the genetic basis of PNH, including PIGA mutations and recently discovered alternative mutations.
  • To outline current therapeutic strategies for PNH, including eculizumab and bone marrow transplantation.

Main Methods:

  • Review of existing literature on PNH pathophysiology, genetics, and treatment.
  • Analysis of the role of complement activation in PNH pathogenesis.
  • Evaluation of the efficacy and indications for eculizumab and bone marrow transplantation.

Main Results:

  • Absence of CD55 and CD59 leads to complement-mediated hemolysis and other PNH symptoms.
  • PIGA mutations are the predominant cause of GPI anchor deficiency, but alternative mutations exist.
  • Eculizumab is effective for severe PNH; bone marrow transplantation is curative but reserved for specific cases.

Conclusions:

  • PNH is a complement-mediated disorder stemming from GPI anchor protein deficiency, primarily due to PIGA mutations.
  • Eculizumab represents a significant therapeutic advance for severe PNH.
  • Bone marrow transplantation remains the definitive cure for PNH, indicated for eculizumab non-responders.